Want to see UPC full AI Analyst Report?
UPC Stock Chart & Stats
$3.39
-$0.40(-10.55%)
At close: 4:00 PM EDT
$3.39
-$0.40(-10.55%)
Day’s Range― - ―
52-Week Range$2.00 - $17.96
Previous CloseN/A
Volume43.59K
Average Volume (3M)955.25K
Market Cap
$2.00M
Enterprise Value-$17.95
Total Cash (Recent Filing)$29.05M
Total Debt (Recent Filing)$9.55M
Price to Earnings (P/E)―
Beta1.91
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding631,761
10 Day Avg. Volume2,486,504
30 Day Avg. Volume955,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00082
P/FCF Ratio>-0.01
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Leverage / Manageable Balance SheetLow debt relative to equity and modest total borrowings provide structural financial flexibility. Manageable leverage reduces near-term solvency risk and preserves capacity to fund R&D or bridge losses via borrowing if needed, making the balance sheet a durable stabilizer while operations recover.
Gross Margin Rebound In 2025A meaningful improvement in gross margin suggests better product mix, pricing or cost control at the production level. Sustained higher gross margins materially improve the path to operating leverage and eventual profitability if revenue stabilizes, making margin recovery a durable operational positive.
Strategic IP Acquisition Expands PipelineAdding five patents broadens the company's intellectual property and long-term R&D options in aging, neurodegenerative and cardiovascular areas. This structural pipeline expansion can create future proprietary revenue streams and improve strategic positioning in specialty therapeutics over the medium term.
Bears Say
Multi-year Revenue DeclineSustained, material top-line contraction erodes scale economics and market position. Reduced revenue weakens pricing power, increases per-unit fixed costs and makes it harder to leverage margin improvements; without a reversal, long-term viability and investment returns are at greater risk.
Persistent Negative Operating And Free Cash FlowOngoing cash burn requires external funding or asset runs to sustain operations. Persistent negative operating and free cash flow limit reinvestment, increase financing risk, and elevate dilution or debt issuance likelihood, constraining the company's ability to execute long-term R&D and commercialization plans.
Concentrated Control And Dilution RiskHigh insider voting control and recent large equity grants concentrate decision-making and reduce minority protections. That governance structure increases the risk of dilutive or self-serving transactions (e.g., all-share acquisitions) and may deter outside investors or complicate future capital raises.
Universe Pharmaceuticals News
UPC FAQ
What was Universe Pharmaceuticals’s price range in the past 12 months?
Universe Pharmaceuticals lowest stock price was $2.00 and its highest was $17.96 in the past 12 months.
What is Universe Pharmaceuticals’s market cap?
Universe Pharmaceuticals’s market cap is $2.00M.
When is Universe Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Universe Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Universe Pharmaceuticals overvalued?
According to Wall Street analysts Universe Pharmaceuticals’s price is currently Overvalued.
Does Universe Pharmaceuticals pay dividends?
Universe Pharmaceuticals does not currently pay dividends.
What is Universe Pharmaceuticals’s EPS estimate?
Universe Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Universe Pharmaceuticals have?
Universe Pharmaceuticals has 631,761 shares outstanding.
What happened to Universe Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Universe Pharmaceuticals?
Currently, no hedge funds are holding shares in UPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Universe Pharmaceuticals
Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.
Technical Analysis
China Pharma Holdings
―
RedHill Biopharma
―
China SXT Pharmaceuticals
―
PainReform
―
Shuttle Pharmaceuticals Holdings, Inc.
―